There are a number of specific characteristics to be considered when developing and manufacturing live bacterial vaccines.
Guido Dietrich
Advertisement
Director of bulk technologies at GlaxoSmithKline Biologicals
Articles by Guido Dietrich
Advertisement
Latest Updated Articles
Developing and Manufacturing Attenuated Live Bacterial VaccinesPublished: October 2nd 2008 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
